Abstract
Multiple sclerosis (MS) exhibits sex bias in disease clinical course as male MS patients develop severe, progressive clinical course with accumulating disability. So far, no factors have been found associating with this sex bias in MS severity. We set out to determine the genetic factor contributing to MS male-specific progressive disease. This is an MS cross-sectional study involving 213 Kuwaiti MS patients recruited at Dasman Diabetes Institute. Exome sequencing was performed on 18 females and 8 male MS patients’ genomic DNA. rs5945430 genotyping was performed using Taqman genotyping assay. Estradiol levels were determined by enzyme-linked immunosorbent assay. Exome analysis revealed a missense variant (rs5945430) in Plexin A3 (PLXNA3) gene (Xq28) associated with male-specific MS severity. Genotyping of 187 MS patients for rs5945430 confirmed the association of rs5945430G with increased disease severity in MS males (p = 0.013; OR 3.8; 95% CI 1.24–11.7) and disability (p = 0.024). Estradiol levels shown to effect PLXNA3 expression were lower in MS males compared to MS females, and they were lower than control rs5945430G males (p = 0.057), whereas MS females had similar estradiol levels to healthy females reducing the level of expressed PLXNA3 GG in MS females. PLXNA3 rs5945430G is associated with increased disease severity in MS male patients. Estradiol is a possible protective factor against the expression of rs5945430G in MS females.
Similar content being viewed by others
References
Al-Temaimi, R., Alroughani, R., Jacob, S., & Al-Mulla, F. (2015). Gender influence in EBV antibody response in multiple sclerosis patients from Kuwait. Journal of Neuroimmunology, 285, 57–61. doi:10.1016/j.jneuroim.2015.05.021.
Bagri, A., Cheng, H. J., Yaron, A., Pleasure, S. J., & Tessier-Lavigne, M. (2003). Stereotyped pruning of long hippocampal axon branches triggered by retraction inducers of the semaphorin family. Cell, 113, 285–299.
Barcellos, L. F., Sawcer, S., Ramsay, P. P., Baranzini, S. E., Thomson, G., Briggs, F., et al. (2006). Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Human Molecular Genetics, 15, 2813–2824. doi:10.1093/hmg/ddl223.
Bashinskaya, V. V., Kulakova, O. G., Boyko, A. N., Favorov, A. V., & Favorova, O. O. (2015). A review of genome-wide association studies for multiple sclerosis: Classical and hypothesis-driven approaches. Human Genetics, 134, 1143–1162. doi:10.1007/s00439-015-1601-2.
Bebo, B. F., Jr., Fyfe-Johnson, A., Adlard, K., Beam, A. G., Vandenbark, A. A., & Offner, H. (2001). Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J Immunol, 166, 2080–2089.
Belyk, M., Kraft, S. J., Brown, S., Pediatric Imaging, N., & Genetics, S. (2015). PlexinA polymorphisms mediate the developmental trajectory of human corpus callosum microstructure. Journal of Human Genetics, 60, 147–150. doi:10.1038/jhg.2014.107.
Bordon, Y. (2014). Autoimmunity: A breakthrough to explain sex bias? Nature Reviews Immunology, 14, 355. doi:10.1038/nri3696.
Bove, R., Healy, B. C., Musallam, A., Glanz, B. I., De Jager, P. L., & Chitnis, T. (2015). Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler. doi:10.1177/1352458515606211.
Caruso, D., Melis, M., Fenu, G., Giatti, S., Romano, S., Grimoldi, M., et al. (2014). Neuroactive steroid levels in plasma and cerebrospinal fluid of male multiple sclerosis patients. Journal of Neurochemistry, 130, 591–597. doi:10.1111/jnc.12745.
Cheng, H. J., Bagri, A., Yaron, A., Stein, E., Pleasure, S. J., & Tessier-Lavigne, M. (2001). Plexin-A3 mediates semaphorin signaling and regulates the development of hippocampal axonal projections. Neuron, 32, 249–263.
Christianson, M. S., Mensah, V. A., & Shen, W. (2015). Multiple sclerosis at menopause: Potential neuroprotective effects of estrogen. Maturitas, 80, 133–139. doi:10.1016/j.maturitas.2014.11.013.
Coleman, M. P., & Perry, V. H. (2002). Axon pathology in neurological disease: A neglected therapeutic target. Trends in Neurosciences, 25, 532–537.
Confavreux, C., Hutchinson, M., Hours, M. M., Cortinovis-Tourniaire, P., & Moreau, T. (1998). Rate of pregnancy-related relapse in multiple sclerosis: Pregnancy in multiple sclerosis group. New England Journal of Medicine, 339, 285–291. doi:10.1056/NEJM199807303390501.
Costa, C., Martinez-Saez, E., Gutierrez-Franco, A., Eixarch, H., Castro, Z., Ortega-Aznar, A., et al. (2015). Expression of semaphorin 3A, semaphorin 7A and their receptors in multiple sclerosis lesions. Multiple Sclerosis Journal, 21, 1632–1643. doi:10.1177/1352458515599848.
Duquette, P., Pleines, J., Girard, M., Charest, L., Senecal-Quevillon, M., & Masse, C. (1992). The increased susceptibility of women to multiple sclerosis. Canadian Journal of Neurological Sciences, 19, 466–471.
Fiedler, S. E., Schillace, R. V., Daniels, C. J., Andrews, S. F., & Carr, D. W. (2010). Myeloid translocation gene 16b is a dual A-kinase anchoring protein that interacts selectively with plexins in a phospho-regulated manner. FEBS Letters, 584, 873–877. doi:10.1016/j.febslet.2010.02.007.
Filippi, M., Preziosa, P., Copetti, M., Riccitelli, G., Horsfield, M. A., Martinelli, V., et al. (2013). Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology, 81, 1759–1767. doi:10.1212/01.wnl.0000435551.90824.d0.
Gomez, C., Burt-Pichat, B., Mallein-Gerin, F., Merle, B., Delmas, P. D., Skerry, T. M., et al. (2005). Expression of Semaphorin-3A and its receptors in endochondral ossification: Potential role in skeletal development and innervation. Developmental Dynamics, 234, 393–403. doi:10.1002/dvdy.20512.
Gubbels Bupp, M. R. (2015). Sex, the aging immune system, and chronic disease. Cellular Immunology, 294, 102–110. doi:10.1016/j.cellimm.2015.02.002.
International Multiple Sclerosis Genetics Consortium, and Wellcome Trust Case Control Consortium, Sawcer, S., Hellenthal, G., Pirinen, M., Spencer, C. C., et al. (2011). Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 476, 214–219. doi:10.1038/nature10251.
Ito, T., Morita, T., Yoshida, K., Negishi, T., & Yukawa, K. (2014). Semaphorin 3A-Plexin-A1 signaling through ERK activation is crucial for Toll-like receptor-induced NO production in BV-2 microglial cells. International Journal of Molecular Medicine, 33, 1635–1642. doi:10.3892/ijmm.2014.1727.
Janssen, B. J., Robinson, R. A., Perez-Branguli, F., Bell, C. H., Mitchell, K. J., Siebold, C., et al. (2010). Structural basis of semaphorin-plexin signalling. Nature, 467, 1118–1122. doi:10.1038/nature09468.
Ji, J. D., Park-Min, K. H., & Ivashkiv, L. B. (2009). Expression and function of semaphorin 3A and its receptors in human monocyte-derived macrophages. Human Immunology, 70, 211–217. doi:10.1016/j.humimm.2009.01.026.
Kallaur, A. P., Kaimen-Maciel, D. R., Morimoto, H. K., Watanabe, M. A., Georgeto, S. M., & Reiche, E. M. (2011). Genetic polymorphisms associated with the development and clinical course of multiple sclerosis (review). International Journal of Molecular Medicine, 28, 467–479. doi:10.3892/ijmm.2011.731.
Kipp, M., Hochstrasser, T., Schmitz, C., & Beyer, C. (2016). Female sex steroids and glia cells: Impact on multiple sclerosis lesion formation and fine tuning of the local neurodegenerative cellular network. Neuroscience and Biobehavioral Reviews, 67, 125–136. doi:10.1016/j.neubiorev.2015.11.016.
Kolk, S. M., Gunput, R. A., Tran, T. S., van den Heuvel, D. M., Prasad, A. A., Hellemons, A. J., et al. (2009). Semaphorin 3F is a bifunctional guidance cue for dopaminergic axons and controls their fasciculation, channeling, rostral growth, and intracortical targeting. Journal of Neuroscience, 29, 12542–12557. doi:10.1523/JNEUROSCI.2521-09.2009.
Kremer, D., Hartung, H. P., & Kury, P. (2015). Targeting semaphorins in MS as a treatment strategy to promote remyelination: A tale of mice, rats and men. Multiple Sclerosis, 21, 1616–1617. doi:10.1177/1352458515608693.
Lee, D. Y., Kim, K. A., Yu, Y. G., & Kim, K. S. (2004). Substitution of aspartic acid with glutamic acid increases the unfolding transition temperature of a protein. Biochemical and Biophysical Research Communications, 320, 900–906. doi:10.1016/j.bbrc.2004.06.031.
Meroni, G., Franco, B., Archidiacono, N., Messali, S., Andolfi, G., Rocchi, M., et al. (1996). Characterization of a cluster of sulfatase genes on Xp22.3 suggests gene duplications in an ancestral pseudoautosomal region. Human Molecular Genetics, 5, 423–431.
Okuno, T., Nakatsuji, Y., Moriya, M., Takamatsu, H., Nojima, S., Takegahara, N., et al. (2010). Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. The Journal of Immunology, 184, 1499–1506. doi:10.4049/jimmunol.0903302.
Perez-Miralles, F., Sastre-Garriga, J., Tintore, M., Arrambide, G., Nos, C., Perkal, H., et al. (2013). Clinical impact of early brain atrophy in clinically isolated syndromes. Multiple Sclerosis, 19, 1878–1886. doi:10.1177/1352458513488231.
Piaton, G., Aigrot, M. S., Williams, A., Moyon, S., Tepavcevic, V., Moutkine, I., et al. (2011). Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. Brain, 134, 1156–1167. doi:10.1093/brain/awr022.
Ribbons, K. A., McElduff, P., Boz, C., Trojano, M., Izquierdo, G., Duquette, P., et al. (2015). Male sex is independently associated with faster disability accumulation in relapse-onset ms but not in primary progressive MS. PLoS ONE, 10, e0122686. doi:10.1371/journal.pone.0122686.
Roxburgh, R. H., Seaman, S. R., Masterman, T., Hensiek, A. E., Sawcer, S. J., Vukusic, S., et al. (2005). Multiple sclerosis severity score: Using disability and disease duration to rate disease severity. Neurology, 64, 1144–1151. doi:10.1212/01.WNL.0000156155.19270.F8.
Runmarker, B., & Andersen, O. (1995). Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain, 118(Pt 1), 253–261.
Sahay, A., Kim, C. H., Sepkuty, J. P., Cho, E., Huganir, R. L., Ginty, D. D., et al. (2005). Secreted semaphorins modulate synaptic transmission in the adult hippocampus. Journal of Neuroscience, 25, 3613–3620. doi:10.1523/JNEUROSCI.5255-04.2005.
Sobrino, A., Mata, M., Laguna-Fernandez, A., Novella, S., Oviedo, P. J., Garcia-Perez, M. A., et al. (2009). Estradiol stimulates vasodilatory and metabolic pathways in cultured human endothelial cells. PLoS ONE, 4, e8242. doi:10.1371/journal.pone.0008242.
Spence, R. D., & Voskuhl, R. R. (2012). Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Frontiers in Neuroendocrinology, 33, 105–115. doi:10.1016/j.yfrne.2011.12.001.
Tran, T. S., Rubio, M. E., Clem, R. L., Johnson, D., Case, L., Tessier-Lavigne, M., et al. (2009). Secreted semaphorins control spine distribution and morphogenesis in the postnatal CNS. Nature, 462, 1065–1069. doi:10.1038/nature08628.
Waimey, K. E., Huang, P. H., Chen, M., & Cheng, H. J. (2008). Plexin-A3 and plexin-A4 restrict the migration of sympathetic neurons but not their neural crest precursors. Development Biology, 315, 448–458. doi:10.1016/j.ydbio.2008.01.002.
Williams, A., Piaton, G., Aigrot, M. S., Belhadi, A., Theaudin, M., Petermann, F., et al. (2007). Semaphorin 3A and 3F: Key players in myelin repair in multiple sclerosis? Brain, 130, 2554–2565. doi:10.1093/brain/awm202.
Xiang, X., Zhang, X., & Huang, Q. L. (2012). Plexin A3 is involved in semaphorin 3F-mediated oligodendrocyte precursor cell migration. Neuroscience Letters, 530, 127–132. doi:10.1016/j.neulet.2012.09.058.
Yaron, A., Huang, P. H., Cheng, H. J., & Tessier-Lavigne, M. (2005). Differential requirement for Plexin-A3 and -A4 in mediating responses of sensory and sympathetic neurons to distinct class 3 Semaphorins. Neuron, 45, 513–523. doi:10.1016/j.neuron.2005.01.013.
Acknowledgements
This research was funded by Kuwait Foundation for the Advancement of Science (KFAS) Grant Number 2012-1302-02.
Author’s Contributions
MQ and MH performed DNA extraction and genotyping experiments. SPJ performed the ELISA experiment. RA facilitated patient sample collection and provided clinical data of MS patients. RAA conceived the project’s design, implementation, exome sequencing, data analysis and wrote the manuscript. All authors have reviewed and approved the final manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Qureshi, M., Hatem, M., Alroughani, R. et al. PLXNA3 Variant rs5945430 is Associated with Severe Clinical Course in Male Multiple Sclerosis Patients. Neuromol Med 19, 286–292 (2017). https://doi.org/10.1007/s12017-017-8443-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-017-8443-0